Therapeutic Efficacy of 7-Chloro-4-(phenylselanyl)quinoline against Oncological Pain Induced by Tumor Progression and Vincristine Treatment

High Resolution Image Download MS PowerPoint Slide Cancer pain is a complex condition often worsened by tumor progression and chemotherapy-induced neuropathy. This study evaluated the therapeutic potential of 7-chloro-4-(phenylselanyl)quinoline (4-PSQ) in mice with Sarcoma 180 (S180)-induced cancer pain and vincristine (VCR)-induced peripheral neuropathy. Male mice were assigned to Control, S180, S180 + VCR, S180 + 4-PSQ, and S180 + VCR + 4-PSQ groups. S180 cells were injected intraplantarly on day 1; VCR was administered days 2–6, and 4-PSQ orally from days 8–17. Nociceptive behavior, tumor progression, and tissue biomarkers were assessed. S180 and VCR caused hyperalgesia, tumor edema, oxidative imbalance, and impaired Na + /K + /Mg 2+ -ATPase activities. 4-PSQ attenuated hyperalgesia, tumor growth, oxidative stress, and immune dysregulation, restoring ATPase activities. Histology confirmed a tumor mass and inflammatory infiltration. These results indicate that 4-PSQ exerts antinociceptive, antioxidant, and immunomodulatory effects, supporting its potential as an adjuvant therapy for cancer pain and chemotherapy-induced neuropathy.